Chimeric factor VIII polypeptides and uses thereof
The present invention provides a VWF fragment comprising the D′ domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.
1. A pharmaceutical composition comprising a chimeric protein and a pharmaceutically acceptable carrier,
wherein the chimeric protein comprises a first polypeptide and a second polypeptide;
wherein the first polypeptide comprises:
(a) a Factor VIII (“FVIII”) protein comprising amino acid residues 1 to 743 of SEQ ID NO: 16 and a B-domain deletion; and
(b) a first immunoglobulin constant region,
wherein the second polypeptide comprises:
(a) a von Willebrand Factor (VWF) fragment comprising a D′ and a D3 domain of VWF, wherein the VWF fragment comprises an alanine substitution for cysteine at residues corresponding to residue 1099 and residue 1142 of SEQ ID NO: 2;
(b) a second immunoglobulin constant region; and
(c) a cleavable linker located between the VWF fragment and the second immunoglobulin constant region,
wherein the first polypeptide and the second polypeptide are linked by a disulfide bond between the first and second immunoglobulin constant regions.
2. The pharmaceutical composition of claim 1 , wherein the first immunoglobulin constant region or portion thereof is a first Fc region and wherein the second immunoglobulin constant region or portion thereof is a second Fc region.
3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in powder form for constitution with a suitable vehicle.
4. The pharmaceutical composition of claim 1 , wherein the FVIII protein comprises an a 3 acidic region, an A3 region, a C1 region, and a C2 region of FVIII comprising amino acids 1649 to 2332 of SEQ ID NO: 16.
5. The pharmaceutical composition of claim 1 , wherein both the first and second immunoglobulin constant region is the Fc fragment of IgG1.
6. The pharmaceutical composition of claim 1 , wherein both the first and second immunoglobulin constant regions are glycosylated.
7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is freeze dried.
8. The pharmaceutical composition of claim 1 , wherein the first polypeptide and the second polypeptide are linked by two disulfide bonds between the first and second immunoglobulin constant regions.
9. The pharmaceutical composition of claim 1 , wherein the cleavable linker is a thrombin cleavable linker.
10. The pharmaceutical composition of claim 1 , wherein the B-domain deletion is a partial deletion of the B domain.
11. The pharmaceutical composition of claim 1 , wherein the VWF fragment consists of a D′ and a D3 domain of VWF.
12. The pharmaceutical composition of claim 1 , wherein the VWF fragment does not include the A1 domain, the A2 domain, the A3 domain, the D4 domain, the B1 domain, the B2 domain, the B3 domain, the C1 domain, the C2 domain, or the CK domain of VWF.
13. The pharmaceutical composition of claim 4 , wherein both the first and second immunoglobulin constant region is the Fc fragment of IgG1.
14. The pharmaceutical composition of claim 13 , wherein the cleavable linker is a thrombin cleavable linker.
15. The pharmaceutical composition of claim 14 , wherein the VWF fragment consists of a D′ and a D3 domain of VWF.
16. A pharmaceutical composition comprising a chimeric protein and a pharmaceutically acceptable carrier,
wherein the chimeric protein comprises a first polypeptide and a second polypeptide;
wherein the first polypeptide comprises:
(a) a Factor VIII (“FVIII”) protein comprising amino acid residues 1 to 743 of SEQ ID NO: 16 and a B-domain deletion; and
(b) a first immunoglobulin constant region,
wherein the second polypeptide comprises:
(a) a von Willebrand Factor (VWF) fragment comprising a D′ and a D3 domain of VWF, wherein the VWF fragment comprises an alanine substitution for cysteine at residues corresponding to residue 1099 and residue 1142 of SEQ ID NO: 2;
(b) a second immunoglobulin constant region; and
(c) a cleavable linker located between the VWF fragment and the second immunoglobulin constant region,
wherein the FVIII protein is a single chain FVIII protein;
wherein the VWF fragment is prevented or inhibited from forming multimers;
wherein the VWF fragment binds to the FVIII protein and does not bind endogenous human VWF;
wherein the first polypeptide and the second polypeptide are linked by a disulfide bond between the first and second immunoglobulin constant regions; and
wherein the pharmaceutical composition is freeze-dried.
17. The pharmaceutical composition of claim 16 , wherein the first immunoglobulin constant region or portion thereof is a first Fc region and wherein the second immunoglobulin constant region or portion thereof is a second Fc region.
18. The pharmaceutical composition of claim 16 , wherein the pharmaceutical composition is in powder form for constitution with a suitable vehicle.
19. The chimeric protein of claim 16 , wherein the FVIII protein comprises an a3 acidic region, an A3 region, a Cl region, and a C2 region of FVIII comprising amino acids 1649 to 2332 of SEQ ID NO: 16.
20. The pharmaceutical composition of claim 16 , wherein both the first and second immunoglobulin constant region is the Fc fragment of IgG1.
21. The pharmaceutical composition of claim 16 , wherein both the first and second immunoglobulin constant regions are glycosylated.
22. The pharmaceutical composition of claim 16 , wherein the first polypeptide and the second polypeptide are linked by two disulfide bonds between the first and second immunoglobulin constant regions.
23. The pharmaceutical composition of claim 16 , wherein the cleavable linker is a thrombin cleavable linker.
24. The pharmaceutical composition of claim 19 , wherein both the first and second immunoglobulin constant region is the Fc fragment of IgG1.
25. The pharmaceutical composition of claim 24 , wherein the first polypeptide and the second polypeptide are linked by two disulfide bonds between the first and second immunoglobulin constant regions.
26. A pharmaceutical composition comprising a chimeric protein and a pharmaceutically acceptable carrier,
wherein the chimeric protein comprises a first polypeptide and a second polypeptide;
wherein the first polypeptide comprises:
(a) a Factor VH (“FVIII”) protein comprising amino acid residues 1 to 740 of SEQ ID NO: 16 and a B-domain deletion; and
(b) a first immunoglobulin constant region,
wherein the second polypeptide comprises:
(a) a von Willebrand Factor (VWF) fragment comprising a D′ and a D3 domain of VWF, wherein the VWF fragment comprises an alanine substitution for cysteine at residues corresponding to residue 1099 and residue 1142 of SEQ ID NO: 2;
(b) a second immunoglobulin constant region; and
(c) a cleavable linker located between the VWF fragment and the second immunoglobulin constant region,
wherein the first polypeptide and the second polypeptide are linked by a disulfide bond between the first and second immunoglobulin constant regions.
27. The pharmaceutical composition of claim 26 , wherein the pharmaceutical composition is in powder form for constitution with a suitable vehicle.
28. The pharmaceutical composition of claim 26 , wherein the FVIII protein comprises an a3 acidic region, an A3 region, a C1 region, and a C2 region of FV111 comprising amino acids 1649 to 2332 of SEQ ID NO: 16.
29. The pharmaceutical composition of claim 26 , wherein both the first and second immunoglobulin constant region is the Fc fragment of IgG1.
30. The pharmaceutical composition of claim 26 , wherein both the first and second immunoglobulin constant regions are glycosylated.
31. The pharmaceutical composition of claim 26 , wherein the pharmaceutical composition is freeze dried.
32. The pharmaceutical composition of claim 26 , wherein the first polypeptide and the second polypeptide are linked by two disulfide bonds between the first and second immunoglobulin constant regions.
33. The pharmaceutical composition of claim 26 , wherein the cleavable linker is a thrombin cleavable linker.
34. The pharmaceutical composition of claim 26 , wherein the B-domain deletion is a partial deletion of the B domain.
35. The pharmaceutical composition of claim 26 , wherein the VWF fragment consists of a D′ and a D3 domain of VWF.
36. The pharmaceutical composition of claim 26 , wherein the VWF fragment does not include the A1 domain, the A2 domain, the A3 domain, the D4 domain, the B1 domain, the B2 domain, the B3 domain, the C1 domain, the C2 domain, or the CK domain of VWF.
37. The pharmaceutical composition of claim 28 , wherein both the first and second immunoglobulin constant region is the Fc fragment of IgG1.
38. The pharmaceutical composition of claim 37 , wherein the cleavable linker is a thrombin cleavable linker.
39. The pharmaceutical composition of claim 38 , wherein the VWF fragment consists of a D′ and a D3 domain of VWF.
40. A pharmaceutical composition comprising a chimeric protein and a pharmaceutically acceptable carrier,
wherein the chimeric protein comprises a first polypeptide and a second polypeptide;
wherein the first polypeptide comprises:
(a) a Factor VII (“FVIII”) protein comprising amino acid residues 1 to 740 of SEQ ID NO: 16 and a B-domain deletion; and
(b) a first immunoglobulin constant region,
wherein the second polypeptide comprises:
(a) a von Willebrand Factor (VWF) fragment comprising a D′ and a D3 domain of VWF, wherein the VWF fragment comprises an alanine substitution for cysteine at residues corresponding to residue 1099 and residue 1142 of SEQ ID NO: 2;
(b) a second immunoglobulin constant region; and
(c) a cleavable linker located between the VWF fragment and the second immunoglobulin constant region,
wherein the FVII protein is a single chain FVIII protein;
wherein the VWF fragment is prevented or inhibited from forming multimers;
wherein the VWF fragment binds to the FVIII protein and does not bind endogenous human VWF;
wherein the first polypeptide and the second polypeptide are linked by a disulfide bond between the first and second immunoglobulin constant regions; and
wherein the pharmaceutical composition is freeze-dried.
41. The pharmaceutical composition of claim 40 , wherein the pharmaceutical composition is in powder form for constitution with a suitable vehicle.
42. The chimeric protein of claim 40 , wherein the FVII protein comprises an a3 acidic region, an A3 region, a C1 region, and a C2 region of FVIII comprising amino acids 1649 to 2332 of SEQ ID NO: 16.
43. The pharmaceutical composition of claim 40 , wherein both the first and second immunoglobulin constant region is the Fc fragment of IgG1.
44. The pharmaceutical composition of claim 40 , wherein both the first and second immunoglobulin constant regions are glycosylated.
45. The pharmaceutical composition of claim 40 , wherein the first polypeptide and the second polypeptide are linked by two disulfide bonds between the first and second immunoglobulin constant regions.
46. The pharmaceutical composition of claim 42 , wherein the cleavable linker is a thrombin cleavable linker.
47. The pharmaceutical composition of claim 40 , wherein both the first and second immunoglobulin constant region is the Fc fragment of IgG1.
48. The pharmaceutical composition of claim 47 , wherein the first polypeptide and the second polypeptide are linked by two disulfide bonds between the first and second immunoglobulin constant regions.